今日のオリジナル番組


詳細を確認
どこでも栽培可能!?「農業イノベーション」
本日配信
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer.
時価総額
12.9 兆円

業績